Hepatitis A

Hepatitis A/B antigen and antibody report issued in last 3 months must be presented prior to Hepatitis A/HepatitisB/Hepatitis A&B vaccination. Extra fee for blood test will be applied if you cannot present a valid report.

Hepatitis A is a liver disease caused by the hepatitis A virus (HAV). Clinical features of hepatitis A are similar to those of other types of viral hepatitis. Typical signs and symptoms of hepatitis A include fever, malaise, loss of appetite, diarrhoea, nausea, abdominal discomfort, or jaundice (yellowing discolouration of the skin and sclera of the eyes, dark urine and pale stool). Not everyone who is infected will have all of the symptoms. Adults have signs and symptoms of illness more often than children, and the severity of disease increases in older age groups. Recovery from symptoms following infection may be slow and may take several weeks or months. Hepatitis A infection does not cause chronic liver disease and is rarely fatal, but it can cause debilitating symptoms and fulminant hepatitis (acute liver failure), which is associated with high mortality. HAV is transmitted primarily by the faecal-oral route, that is when an uninfected person contacts or ingests objects, food or water that has been contaminated with the faeces of an infected person. The virus can also be transmitted through close physical contact with an infectious person including sexual contact and not limited to anal-oral contact. Hepatitis A outbreaks among men who have sex with men (MSM) have been reported. Waterborne outbreaks, though infrequent, are usually associated with sewage-contaminated or inadequately treated water. The incubation period of hepatitis A is usually 14 – 28 days.

Hepatitis A vaccination is a safe and effective means to prevent the infection. Persons who are at increased risk for acquiring hepatitis A and persons with increased risk for severe adverse consequences should discuss with their doctors about hepatitis A vaccination for personal protection. Travellers to endemic areas of hepatitis A, persons with clotting factors disorders receiving plasma-derived replacement clotting factors, persons with chronic liver diseases and men who have sex with men (MSM) are recommended to have hepatitis A vaccination.